LMLaetitia Marisa

Laetitia Marisa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Laetitia Marisa has a total of 130 co-authors. Here are the top co-authors by number of shared publications:

  • Jean-Noël Freund

    Universit e de Strasbourg, Inserm, IRFAC/UMR-S1113, Strasbourg, France

    3 shared publications
  • Ada Collura

    Sorbonne Université, UPMC Univ Paris 06, INSERM, UMRS 938, SIRIC CURAMUS, Equipe Instabilité Des Microsatellites Et Cancer, Equipe Labellisée Par La Ligue Contre Le Cancer, Centre de Recherche Saint Antoine, Paris, France

    2 shared publications
  • Alex Duval

    Sorbonne Université, UPMC Univ Paris 06, INSERM, UMRS 938, SIRIC CURAMUS, Equipe Instabilité des Microsatellites et Cancer, Equipe Labellisée par la Ligue Contre le Cancer, Centre de Recherche Saint Antoine, Paris, F-75012, France

    2 shared publications
  • Anaïs Lagrange

    Sorbonne Université, UPMC Univ Paris 06, INSERM, UMRS 938, SIRIC CURAMUS, Equipe Instabilité des Microsatellites et Cancer, Equipe Labellisée par la Ligue Contre le Cancer, Centre de Recherche Saint Antoine, Paris, F-75012, France

    2 shared publications
  • Elisabeth Martin

    Université de Strasbourg, Inserm, IRFAC UMR-S1113, 67200, Strasbourg, France

    2 shared publications
  • Eric Letouzé

    Nantes Université, Inserm, CNRS, Université d’Angers, CRCI2NA, Nantes, France

    2 shared publications

Latest Publications

  • Classification et caractérisation des cancers colorectaux par approches omiques

    by Laetitia Marisa

    Le cancer du côlon (CC) est l'un des cancers les plus fréquents et les plus mortels en France et dans le monde. Près de la moitié des patients décèdent dans les 5 ans suivant le diagnostic. La classification clinique en stade histologique et la classification moléculaire selon les formes d'instabilité du génome (l'instabilité des microsatellites (MSI), l'instabilité chromosomique (CIN) et l'hyperméthylation des promoteurs (CIMP)) ne suffisent pas à définir des entités homogènes du point de vue moléculaire et à prédire de manière efficace la récidive. Pour améliorer la prise en charge des patients, il apparaît indispensable de mieux appréhender la diversité de la maladie afin de trouver des marqueurs pronostiques et prédictifs efficaces. Mon travail de thèse a donc été d'étudier la diversité des CC à l'échelle moléculaire par l'utilisation d'approches omiques sur une large cohorte de patients. Il a abouti à l'établissement d'une classification transcriptomique robuste de ce cancer dans son ensemble, validée sur des données indépendantes, et à la caractérisation fine de chacun des sous-types. Six sous-types ont ainsi été définis présentant des caractéristiques clinico-pathologiques, des altérations moléculaires de l'ADN, des enrichissements de signatures liées aux lésions et cellules d'origines, des voies de signalisation dérégulées et des survies bien distinctes. Les résultats de ce travail ont été confortés par un travail de classification consensus mis en place avec un consortium de travail international auquel j'ai participé. Ces résultats ont permis de confirmer que le cancer colorectal n'est pas une maladie homogène. Ils ouvrent de nouvelles perspectives pour l'établissement de signatures pronostiques et la recherche de cibles pour de nouveaux traitements ainsi que pour l'évaluation de la réponse au traitement au sein d'essais cliniques.

  • The atypical cadherin MUCDHL antagonizes colon cancer formation and inhibits oncogenic signaling through multiple mechanisms

    by Marine Beck, Mathilde Baranger, Ahlam Moufok-Sadoun, Emilie Bersuder, Isabelle Hinkel, Georg Mellitzer, Elisabeth Martin, Laetitia Marisa, Isabelle Duluc, Aurelien de Reynies, et al.

    Cadherins form a large and pleiotropic superfamily of membranous proteins sharing Ca2+-binding repeats. While the importance of classic cadherins such as E- or N-cadherin for tumorigenesis is acknowledged, there is much less information about other cadherins that are merely considered as tissue-specific adhesion molecules. Here, we focused on the atypical cadherin MUCDHL that stood out for its unusual features and unique function in the gut. Analyses of transcriptomic data sets (n > 250) established that MUCDHL mRNA levels are down-regulated in colorectal tumors. Importantly, the decrease of MUCDHL expression is more pronounced in the worst-prognosis subset of tumors and is associated with decreased survival. Molecular characterization of the tumors indicated a negative correlation with proliferation-related processes (e.g., nucleic acid metabolism, DNA replication). Functional genomic studies showed that the loss of MUCDHL enhanced tumor incidence and burden in intestinal tumor-prone mice. Extensive structure/function analyses revealed that the mode of action of MUCDHL goes beyond membrane sequestration of ß-catenin and targets through its extracellular domain key oncogenic signaling pathways (e.g., EGFR, AKT). Beyond MUCDHL, this study illustrates how the loss of a gene critical for the morphological and functional features of mature cells contributes to tumorigenesis by dysregulating oncogenic pathways.


  • Top Cited Papers

    Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features

    by Francesco Puleo, Rémy Nicolle, Yuna Blum, Jérôme Cros, Laetitia Marisa, Pieter Demetter, Eric Quertinmont, Magali Svrcek, Nabila Elarouci, Juan Iovanna, et al.


  • Open Access

    Targeting nonsense-mediated mRNA decay in colorectal cancers with microsatellite instability

    by A’dEm Bokhari, Vincent Jonchere, Anaïs Lagrange, Romane Bertrand, Magali Svrcek, Laetitia Marisa, Olivier Buhard, Malorie Greene, Anastasia Demidova, Jieshuang Jia, et al.

    Nonsense-mediated mRNA decay (NMD) is responsible for the degradation of mRNAs with a premature termination codon (PTC). The role of this system in cancer is still quite poorly understood. In the present study, we evaluated the functional consequences of NMD activity in a subgroup of colorectal cancers (CRC) characterized by high levels of mRNAs with a PTC due to widespread instability in microsatellite sequences (MSI). In comparison to microsatellite stable (MSS) CRC, MSI CRC expressed increased levels of two critical activators of the NMD system, UPF1/2 and SMG1/6/7. Suppression of NMD activity led to the re-expression of dozens of PTC mRNAs. Amongst these, several encoded mutant proteins with putative deleterious activity against MSI tumorigenesis (e.g., HSP110DE9 chaperone mutant). Inhibition of NMD in vivo using amlexanox reduced MSI tumor growth, but not that of MSS tumors. These results suggest that inhibition of the oncogenic activity of NMD may be an effective strategy for the personalized treatment of MSI CRC.


  • Top Cited Papers
    Open Access

    Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes

    by Gwen Lomberk, Yuna Blum, Rémy Nicolle, Asha Nair, Krutika Satish Gaonkar, Laetitia Marisa, Angela Mathison, Zhifu Sun, Huihuang Yan, Nabila Elarouci, et al.

    Recent studies have offered ample insight into genome-wide expression patterns to define pancreatic ductal adenocarcinoma (PDAC) subtypes, although there remains a lack of knowledge regarding the underlying epigenomics of PDAC. Here we perform multi-parametric integrative analyses of chromatin immunoprecipitation-sequencing (ChIP-seq) on multiple histone modifications, RNA-sequencing (RNA-seq), and DNA methylation to define epigenomic landscapes for PDAC subtypes, which can predict their relative aggressiveness and survival. Moreover, we describe the state of promoters, enhancers, super-enhancers, euchromatic, and heterochromatic regions for each subtype. Further analyses indicate that the distinct epigenomic landscapes are regulated by different membrane-to-nucleus pathways. Inactivation of a basal-specific super-enhancer associated pathway reveals the existence of plasticity between subtypes. Thus, our study provides new insight into the epigenetic landscapes associated with the heterogeneity of PDAC, thereby increasing our mechanistic understanding of this disease, as well as offering potential new markers and therapeutic targets.


  • Open Access

    The Cdx2 homeobox gene suppresses intestinal tumorigenesis through non–cell-autonomous mechanisms

    by Camille Balbinot, Olivier Armant, Nabila Elarouci, Laetitia Marisa, Elisabeth Martin, Etienne De Clara, Alina Onea, Jacqueline Deschamps, Felix Beck, Jean-Noël Freund, et al.

    Developmental genes contribute to cancer, as reported for the homeobox gene Cdx2 playing a tumor suppressor role in the gut. In this study, we show that human colon cancers exhibiting the highest reduction in CDX2 expression belong to the serrated subtype with the worst evolution. In mice, mosaic knockout of Cdx2 in the adult intestinal epithelium induces the formation of imperfect gastric-type metaplastic lesions. The metaplastic knockout cells do not spontaneously become tumorigenic. However, they induce profound modifications of the microenvironment that facilitate the tumorigenic evolution of adjacent Cdx2-intact tumor-prone cells at the surface of the lesions through NF-κB activation, induction of inducible nitric oxide synthase, and stochastic loss of function of Apc. This study presents a novel paradigm in that metaplastic cells, generally considered as precancerous, can induce tumorigenesis from neighboring nonmetaplastic cells without themselves becoming cancerous. It unveils the novel property of non–cell-autonomous tumor suppressor gene for the Cdx2 gene in the gut. Graphical Abstract


  • Tu1986 The Cadherin-Related Mucdhl Is Decreased in Stem Cell-Like Colon Tumors and Inhibits β-Catenin Signaling in a Non-Classical Way

    by Mathilde Baranger, Georg Mellitzer, Laetitia Marisa, Elisabeth Martin, Isabelle Duluc, Jean-Noël Freund, Isabelle Gross

  • High-resolution analysis of DNA copy number alterations in rectal cancer

    by Jérôme Doyen, Eric Letouzé, Laetitia Marisa, Aurélien de Reyniès, Gérard Milano, Marie-Christine Etienne-Grimaldi, Sylviane Olschwang, Jochen Gaedcke, Michael Ghadimi, Jean-Pierre Gérard

    This study aimed to determine the candidate genes and chromosomal imbalances capable of predicting occurrences of metastasis in patients with rectal cancer. Fresh frozen tumor tissues from 80 patients with rectal cancer were prospectively collected and analyzed using Affymetrix HG-U133 Plus 2.0 gene expression arrays and high-resolution Illumina single-nucleotide polymorphism (SNP) arrays. Endpoints of the study were metastasis-free survival (MFS) and cancer-specific survival (CSS). The median follow-up was 102 months (1–146). Deletions of 8p and 1p36-35 correlated with worse MFS (p = 0.005 and p = 0.01, respectively) and CSS (p = 0.001 and p = 0.01, respectively). Multivariate analysis identified 8p deletion as an independent prognostic factor for MFS (p = 0.04) and CSS (p = 0.003); 97 genes located on the 8p chromosome were significantly underexpressed in tumors with 8p deletion. This study shows for the first time in rectal cancer an independent correlation of 8p deletion with MFS and CSS and highlights potential new tumor suppressor genes. Diese Studie zielt darauf ab, Kandidatengene und chromosomale Ungleichgewichte vorherzusagen und das Auftreten von Metastasen bei Rektumkarzinompatienten zu bestimmen. Frisch gefrorenes Tumorgewebe von 80 Patienten mit Rektumkarzinom wurde prospektiv erfasst und mit Affymetrix-(HG-U133-Plus-2.0)-Genexpressionsarrays und hochauflösenden Illumina-Single-Nukleotid-Polymorphismus-(SNP-)Arrays analysiert. Endpunkte der Studie waren fernmetastasenfreies Überleben (MFU) und krebsspezifisches Überleben (KSU). Die mediane Nachbeobachtungszeit betrug 102 Monate (1−146 Monate). Die Deletionen von 8p und 1p36−35 waren mit schlechterem MFU (jeweils p = 0,005 und p = 0,01) und KSU (jeweils p = 0,001 und p = 0,01) korreliert. Die multivariate Analyse identifizierte − 8p als unabhängigen prognostischen Faktor für MFU (p = 0,04) und KSU (p = 0,003). In Tumoren mit einer 8p-Deletion waren 97 Gene auf Chromosom 8p signifikant unterexprimiert. Diese Studie zeigt zum ersten Mal in Rektumkarzinomen eine unabhängige Korrelation von − 8p mit MFU und KSU und bringt somit potentielle neue Tumorsuppressorgene hervor.


  • Abstract 5065: Gene expression profiling of colon adenocarcinomas reveals six prototypic molecular subtypes with distinct clinical and molecular characteristics

    by Laetitia Marisa, Laure Vescovo, Aurélien Reyniès, Alex Duval, Marie-Christine Etienne-Grimaldi, Marie-Pierre Gaub, Dominique Guenot, Sylvain Kirzin, Gérard Milano, Sylviane Olschwang, et al.

    Purpose: The purpose of our study was to build up a molecular classification of colon cancers (CC) and to further identify a molecular signature that correlated with disease outcome through a genome-wide DNA and mRNA expression analysis. Material: Fresh frozen tumor tissues from 750 patients with stage I to IV CC were analyzed for anatomo-clinical characteristics and common DNA alterations including KRAS, BRAF, TP53 mutations, MMR (Mismatch Repair system) and CIMP (CpG island methylator phenotype) status. Among the 750 tumors, 443 were screened for pangenomic alteration and expression profiles using Affymetrix U133P2 chips and CGH arrays. Results: A robust approach based on unsupervised hierarchical clusterings of the 443 tumors revealed six main prototypic molecular subtypes with distinct clinical/molecular correlations and outcomes. The first (C1), fifth (C5) and sixth (C6) subtypes were more frequently CIN+ (chromosomal instability assessed by CGHa), TP53 mutant and left-sided tumors, without any molecular or clinical annotation able to clearly discriminate these three subgroups except the low relapse rate observed in the C5 subgroup (21.6% versus 30.9% and 39.3% in C1 and C6 subgroups, respectively). C2 was enriched for patients with deficient MMR (80.7%), CIMP+ (62.5%), BRAF mutant (37.3%) and right-sided (71%) CC with low relapsing rate (19.7%). C3 was enriched for KRAS mutant (76.2%) and right-sided tumors (57.8%). C4 included more CIMP+ (35.4%), BRAF mutant (25%), right-sided (64.2%) and relapsing (47.2%) CC. Of those 6 subtypes, C4 and C2 (dMMR) appeared to be the most segregated subtypes, others being less distant to each other. Although not significant, there was a trend in favor of a prognostic value of the six-subgroup classification, with C1, C4 and C6 subgroups having a relative poor outcome, and C2 and C5 a relative good outcome (65%, 64%, 63%, 77% and 83% 5-year disease-free survival, respectively; p=0.12). Using the limited number of molecular features available from 6 public datasets, we validated the molecular and clinical characteristics of C2, as well as the higher rate of relapse observed in C4. The prognostic value of the six-subtype classification was significant when applied to one independent dataset of 304 CC (p=0.012), with a worse prognosis confirmed for C1 and C4, and a better prognosis for C2 and C5. Conclusion: Our results suggest that CC develop as distinct molecular entities evolving through multiple pathways on the basis of several molecular features that may not result in a single but in several prognostic signatures according to each molecular subtype. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5065. doi:1538-7445.AM2012-5065


  • Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis

    by Coralie Dorard, Aurélie de Thonel, Ada Collura, Laetitia Marisa, Magali Svrcek, Anaïs Lagrange, Gaetan Jego, Kristell Wanherdrick, Anne Laure Joly, Olivier Buhard, et al.

    Heat shock proteins (HSPs) are necessary for cancer cell survival. We identified a mutant of HSP110 (HSP110ΔE9) in colorectal cancer showing microsatellite instability (MSI CRC), generated from an aberrantly spliced mRNA and lacking the HSP110 substrate-binding domain. This mutant was expressed at variable levels in almost all MSI CRC cell lines and primary tumors tested. HSP110ΔE9 impaired both the normal cellular localization of HSP110 and its interaction with other HSPs, thus abrogating the chaperone activity and antiapoptotic function of HSP110 in a dominant-negative manner. HSP110ΔE9 overexpression caused the sensitization of cells to anticancer agents such as oxaliplatin and 5-fluorouracil, which are routinely prescribed in the adjuvant treatment of people with CRC. The survival and response to chemotherapy of subjects with MSI CRCs was associated with the tumor expression level of HSP110ΔE9. HSP110 may thus constitute a major determinant for both prognosis and treatment response in CRC.